

Toxic Joint Syndrome A New Therapeutic Option

*Ronald Shapiro MD, PhD, FACP
Clinical Associate Professor of Medicine, University of Toledo
And*

*Charles A. Bertrand, M.D., F.A.C.P., F.A.C.C. (ret.)
Clinical Associate Professor of Medicine, Medical University of South Carolina and New York
Medical College (ret.)*

Part II of a 2-part article

(We would appreciate your feedback: toxicjoint@medicineuptotheminute.com)

Toxic Joint Syndrome (TJS) was defined and characterized in the first segment of this series. Certainly there are benefits to current therapeutic options; however, there are also significant disadvantages that include treatment associated morbidity and mortality, reduced quality of life, impaired performance, income loss from escalating debility, and significant monetary burdens from medication and procedures.

For example, consider the direct expense incurred during the course of a single osteoarthritic toxic knee joint syndrome. Costs might begin with diagnostics and medication and extend to joint replacement. The lifetime expense of this single toxic joint could range from \$30,000 to \$50,000, and over the years the pill consumption could be over 15,000.

An innovative treatment option to address the complaints, debility, associated treatment limitations, and cost of a toxic joint resides in new technology. In 2005, a safe, effective, FDA cleared modality to relieve knee pain and improve mobility was reported employing a third generation device called the MedLite[®]. The technology was validated in a statistically significant blinded, three period, complete crossover study.

Recently, a new option for patients and physicians has emerged with the introduction of a new biomedical computer for joint pain. Programmed with the proprietary “pain Sensorpeutic™ algorithm”, it is a sophisticated medical/consumer technotherapy device designed for Toxic Joint Syndrome. This unique device has undergone rigorous research and development by a team which includes pain management physicians. It offers a new supplemental or standalone tool for safe and effective treatment of Toxic Joint Syndrome.

The NINS[®] (non-invasive neurovascular stimulation) operating system is resident in this biomedical computer which employs multiple dynamic energies (Photonic and Thermal Kinetic). Sensing technology located in the treatment head measures and collects bio-physiologic data at the skin surface and deeper structures which is fed back to the operating system. The multiple energies and feedback information are integrated through specialized hardware and software through use of a proprietary algorithm that “learns” from the collected sensory responses. These collected responses are submitted to the algorithm which manipulates multiple treatment parameters thousands of times a second. “Customized” therapy is generated which is unique to the user’s: i) condition, and ii) sensory response. This sophisticated biomedical computer for the treatment of Toxic Joint Syndrome carries the brand name of WilloMD.™

Toxic Joint Syndrome A New Therapeutic Option

The “Sensorpeutic” algorithm that delivers the customized energy is known as Veriscription™ (like an electronic prescription). In addition to the high treatment success of this technology, is the observation that the phenomenon of adaptation or tachyphylaxis (a decreasing response of the body to repeated stimuli such as medication or therapy) is overcome. This means that the device can be effectively used as often and for as long as the users wish, and they can expect continued and cumulative benefits.

A statically significant controlled, randomized, double blinded, IRB approved medical study, conducted by a hospital based independent medical team provided conclusive validation of the technology. The study has confirmed that the WillomD™ produced measurable, statistically significant benefit for those with Toxic Knee Joint Syndrome. Benefits confirmed were knee pain relief, greater flexion, and enhanced performance and functional abilities, with no adverse side effects.

Thousands of successful clinical patient treatment outcomes also contribute to the validation of the WillomD’s efficacy and safety. Over ninety percent of the time, WillomD users obtain significant, predictive, reproducible and cumulative effects that afford them reduced pain, improved mobility, enhanced performance and an improved quality of life.

In the simplest terms, this innovative system works by increasing circulation, slowing nerve signals, reducing nerve sensitivity, promoting cleansing of joints congested with inflammatory and intra-articular waste debris, elevating the body’s natural pain fighters, blocking pain receptors and creating “nerve confusion.”

Before and after each treatment with the device, users are encouraged to record subjective and objective parameters regarding their pain and functional abilities. This provides tangible evidence of the treatment effect

With the advent of this emerging technology, individuals, physicians, and allied health providers have an effective, safe, and affordable additional therapeutic tool to treat a Toxic Joint Syndrome. Advantages of WillomD therapy include:

- Portability, easy cleaning for safe multi-individual use.
- Significant pain reduction and improved performance permitting individuals to engage in fitness development, thereby lowering their risk of premature cardiac and non-cardiac mortality.
- Reduction in pain medication which diminishes medication related morbidity and mortality.
- Offering substitute therapy for those who are unable to use, or prefer not to take medication.
- Treatment prior to and in combination with physical therapy to reduce pain, increase mobility, and enhance rehab performance.
- Treatment prior to and in combination with surgery to reduce pain, promote healing, improve mobility and enhance rehab performance.
- Managing Toxic Joint Syndromes in patients temporarily or permanently ineligible for surgery.

Toxic Joint Syndrome A New Therapeutic Option

- Providing adequate symptomatic relief to allow postponement of joint replacement should this be desired or required.
- Treatment in the office or clinic settings can provide therapy and improve patient satisfaction, especially during delays while waiting to see a health care provider.
- Reduce the monetary burden incurred in short and long term management of a toxic joint syndrome.

The foregoing details situations where the WilloMD can supplement traditional therapies, provide a treatment alternative when traditional therapies may be unavailable or contraindicated, and may offer an effective standalone approach. The cost/benefit ratio of this approach contrasted with traditional therapies is considerably lower.

A growing number of individuals are seeking new solutions to manage their TJS. News programs, lay and professional publications and medication advertising campaigns have increased awareness of adverse medication effects. Health care professionals are observing a growing portion of the population who prefer to diminish or stop their pill intake. Consumers and providers are seeking alternatives to supplement or substitute traditional treatment in an attempt to relieve symptoms and regain performance.

Now patients and doctors have an additional safe and effective therapeutic option to treat Toxic Joint Syndrome, as well as other body areas that fit under the treatment arc of the device. In view of the new information reported from Stanford Medical School, it is exciting that use of this Sensorpeutic technology could potentially be very valuable in addressing early treatment of osteoarthritis. If indeed we can safely and effectively dampen inflammatory joint destruction early on in the disease, imagine the implications: less joint destruction, reduced debility from toxic joints, reduced cost of toxic joint care, fewer adverse events from medications, and an improved quality of life for millions are but a few advantages.

The advanced Sensorpeutic technology, effectiveness, safety, and cost of the WilloMD offers a practical therapeutic option. Very quickly, an individual or health care professional can determine if this technology will be beneficial. Applications are designed for use by the young, the elderly, the debilitated, the performance athlete, and it can be used in animals. The WilloMD is truly “global game changing” technology.

Additional information can be obtained at: www.toxicjoint.com

Acknowledgement:

The authors wish to extend their appreciation to Physician Technology’s CEO David B. Sutton for his strong support and contribution of innovative information, documents, and data.

###